Bear,

my base case is that RVX gets bought out well before we get to FDA approvals being needed. I am assuming that some big pharma writes a mega check to buy out both RVX and Zenith in one fell swoop.  

What makes this a likely case, is the large stock ownership by our friends in Shenzhen.  It becomes easy for a BP to coax out that 40% of shares.  After that, they hopefully make a public bid for all listed shares of RVX...plus a private bid for Zenith.  They can haggle about the eventual price...but the check will be for both companies...not just one.

Given the Humira like nature of Apabetalone (thanks for pointing that out Makalu!), it is inconceivable that some BP does not figure this all out.  Plus the 20 or so molecules that RVX can trot out for future Phase 1 trials, makes it a slam dunk.  Who knows...perhaps we even get a bidding war?